Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.
复制标题

DOI:
10.1038/s41467-017-02349-8
复制
发表时间:
2018-02-05
影响因子:
16.6
通讯作者:
Daelemans D
Daelemans D
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Neggers JE;Kwanten B;Dierckx T;Noguchi H;Voet A;Bral L;Minner K;Massant B;Kint N;Delforge M;Vercruysse T;Baloglu E;Senapedis W;Jacquemyn M;Daelemans D

文献摘要

参考文献

被引文献

相似文献

解开小分子的作用机制和分子靶点仍然是药物开发中的一大挑战。虽然许多抗癌药物针对的是遗传易损性,但功能丧失筛查未能识别药物作用机制中的必要基因。在这里,我们报告CRISPRres,一种基于CRISPR-CAS的基因筛查方法,用于快速获得和识别基本基因中的耐药突变。它利用CRISPR-Cas诱导的非同源末端连接(NHEJ)修复所产生的局部遗传变异来产生各种功能性的框内突变。使用大型sgRNA平铺文库和已知的药物-靶点对,我们验证了它是一种靶标识别方法。我们将CRISPRres应用于抗癌药物KPT-9274,并确定烟酰胺磷酸核糖转移酶(NAMPT)为其主要靶点。这些结果提供了一种强大而简单的遗传方法来创造许多蛋白质变体,与正向选择相结合,可以用于揭示小分子抑制剂的细胞靶点。癌症治疗药物旨在针对遗传脆弱性,但功能丧失筛查往往无法在药物机制研究中识别关键基因。在这里,作者展示了CRISPRres,它利用插入形成产生的帧内变异来发现基因-药物相互作用。
Unraveling the mechanism of action and molecular target of small molecules remains a major challenge in drug discovery. While many cancer drugs target genetic vulnerabilities, loss-of-function screens fail to identify essential genes in drug mechanism of action. Here, we report CRISPRres, a CRISPR-Cas-based genetic screening approach to rapidly derive and identify drug resistance mutations in essential genes. It exploits the local genetic variation created by CRISPR-Cas-induced non-homologous end-joining (NHEJ) repair to generate a wide variety of functional in-frame mutations. Using large sgRNA tiling libraries and known drug–target pairs, we validate it as a target identification approach. We apply CRISPRres to the anticancer agent KPT-9274 and identify nicotinamide phosphoribosyltransferase (NAMPT) as its main target. These results present a powerful and simple genetic approach to create many protein variants that, in combination with positive selection, can be applied to reveal the cellular target of small-molecule inhibitors. Cancer therapy drugs are designed to target genetic vulnerabilities, but loss-of-function screens often fail to identify essential genes in drug mechanism studies. Here the authors demonstrate CRISPRres, which exploits in-frame variation generated by indel formation to discover gene-drug interactions.
蛋白酶体抑制剂硼替佐米的耐药机制
DOI: 10.1186/2050-7771-1-13
发表时间: 2013-03-01
期刊: Biomarker research
影响因子: 11.1
作者:
Lü S;Wang J
通讯作者: Wang J
DOI: 10.1093/nar/gku936
发表时间: 2014-12-16
影响因子: 14.9
作者:
Brinkman EK;Chen T;Amendola M;van Steensel B
通讯作者: van Steensel B
DOI: 10.1107/s0907444909052925
发表时间: 2010-02
期刊: Acta crystallographica. Section D, Biological crystallography
影响因子: --
作者:
Adams PD;Afonine PV;Bunkóczi G;Chen VB;Davis IW;Echols N;Headd JJ;Hung LW;Kapral GJ;Grosse-Kunstleve RW;McCoy AJ;Moriarty NW;Oeffner R;Read RJ;Richardson DC;Richardson JS;Terwilliger TC;Zwart PH
通讯作者: Zwart PH
DOI: 10.1182/blood-2016-06-724831
发表时间: 2017-04-20
期刊: BLOOD
影响因子: 20.3
作者:
Fulciniti, Mariateresa;Martinez-Lopez, Joaquin;Munshi, Nikhil C.
通讯作者: Munshi, Nikhil C.
DOI: 10.1038/nsmb1105
发表时间: 2006-07-01
影响因子: 16.8
作者:
Khan, Javed A.;Tao, Xiao;Tong, Liang
通讯作者: Tong, Liang